Ipca Laboratories

Emerging Markets In Asia And Africa Will Fuel Healthcare Demand

AnalystHighTarget

Not Invested

Consensus Narrative from 17 Analysts

Published

28 Jun 25

AnalystHighTarget's Fair Value

₹1,810.00

27.5% undervalued

08 Aug

₹1,311.50

-10.0%

-0.7%

-10.0%

-0.7%

You can edit this narrative until Jun 28 9:15 PM. Then, changes will post as Updates.

Author's Valuation

₹1.8k

27.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

₹1.81k

27.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.37%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹18.83b

Earnings '28

34.84x

PE Ratio '28

₹655.99b

Market Cap '28

₹655.99b

Market Cap '28

253.97m

No. shares '28

₹2.58k

Share Price '28

₹2.58k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹1.80k

Fair Value '25